saw sale underli flat posit mix acq biiv
strong cost control group achiev ep growth
see eros us lantu franchis higher charg
donut hole base franchis rare diseas vaccin
consum dupix off-set continu diabet
pressur declin european establish product tail new
cfo gave year cost guidanc limit combin sg growth
around enough drive margin leverag despit
need pay away profit share partner regeneron like
new head present result cull program
plan reinvest earlier project flat spend
new manag come power credenti cost control
 manag join point lantu renvela
eros eas still need done continu portfolio
reorient dilut group tail product continu
declin pa cash gener power unit remain strong
alongsid vaccin key contributior npv see stock
under-valued today look rerat past headwind fade
dupi continu expand indic
valuat sanofi trade pe discount global
peer ev/npv sanofi trade discount global peer
cheapest global major metric
valuat metric
price-to-earnings rel local market
price month
price rel chart measur perform
close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
sanofi-aventi pharmaceut group engag research
develop manufactur market healthcar product
vaccin sanofi pasteur
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
blue sky scenario assum full pipelin success stronger
growth rate diabet
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
grey sky assum pipelin success greater declin
diabet driven greater gener competit lantu poor
uptak lixilan
price rel chart measur perform
close
spot exchang rate
chang forecast
made limit overal chang although new fx algorithm suggest broadli
neutral fx environ saw headwind remov
number earli stage product make limit differ either earn model
npv
figur chang forecast
diabet annual declin cs
sg sale
buy back cs
gm impact donut
hole extra spend
yr
cer
turn profit
buy-back focu
debt reduct acq
ep growth weight
chang
envelop
manag
sutimlimab
dupix
dupix
olipudas
figur eu us major pharma compar valuat
sanofi premium/ discount eu
sanofi premium/ discount global
sanofi result commentari
compani sale cer continu new growth phase
start top end guidanc
us lantu us sevelam
busi ep cer
double-digit growth specialti care- cer/c
diseas franchis driven core franchis pomp
gaucher fabri
multipl sclerosi franchis return driven aubagio
oncolog growth legaci oncolog portfolio support em
perform look forward expand portfolio eu launch
blood disord franchis u/l perform remain solid
immunolog franchis sale annualis
special care built three pillar
dupix fda approv treatment moderate-to-sever asthma
octob label differenti well posit compet benefit good
data sc home inject believ dupi differenti
depend oral corticosteroid
adult ad cover half step edit launch ex-
us countri includ japan remain confid dupi
advanc cscc cutan
squamou cell carcinoma data show respons rate product
incdic nccn guidelin
ema decis expect
cablivi first therapeut approv eu treatment ttp mortal rate
current soc huge unmet need
fda approv eu us ttp us launch late
launch germani launch nordic
vaccin sale cer driven flu menactra
due time cdc buy middl east buy
praluent diabet
global diabet anticip
admelog sale due access manag medicaid expect
net price declin reduc coverag part higher rebat
zynquista pdufa date march ema decis
praluent sale momentum driven us exclus
access ersx
higher us rebat expect impact sale
chc franchis sale balanc growth geographi
key categori leadership continu drive higher growth peer line
synergi expect bi consum acusit
em led latin america
strong earli cough cold divest
like continu
us driven digest skin care sale
em core strength sanofi driven asia particularli china
currenc impact modest due strength usd
compani sale due strengthen usd
expect posit fx impact
 cer invest late-stag pipelin growth
sg cer despit new launch roll-out dupi
gross margin gm larg unchang expect gm
rebat net increas coverag gap
oper expens line guidanc expect growth
opex futur year
propos consecut increas annual dividend
import part valu proposit sharehold
end dec net debt increas
share repurchas prioriti pay debt
progress divi chang buy back strategi
busi ep cer express confid return growth
includ acq divest invest growth weight
fx impact cer jan exchang rate
 updat john reed head
commit innov solut prioritis patient need import
lot effort faster decis make
long-term object first best-in-class aim biolog vs
intern deriv vs today
sanofi expect maintain annual budget
priorit invest unmet need highest
total number research increas
clinic stage product vs product vs portfolio
shift specialti care discontinu develop research product
sanofi breadth therapeut platform nanobodi lentiviru
antibodi platform focus oncolog immunolog nanobodi
sanofi look appli data scienc machin learn ai
cancer
tri bi-specif
novel combin tgfb
isatuximab posit icardia data bla develop io
high ceacam express repres lung cancer
patient pivot studi begin
replac weekli product mean half-lif start
assum favour outcom dialogu fda
sutilimab cold agglutin diseas us eu patient
underway phase result expect potenti pipelin product
preserv kidney function us eu
anti-rsv children affected/year one inject month posit
result receiv us breakthrough prime design
dupi nasal polpi met primari end point
nme addit indic potenti submit
continu busi momentum support launch
object
import step evolv special care oncolog
sanofi manag june
 expect cost save investor seem gone quiet
updat cfo
look make dedic announc major cost cut exercis
want ensur opex growth inflat growth sanofi midterm
target opex growth mid-term seek effici
involv major cost reduct area reinvest potenti growth
area key sanofi want give mid-tern messag consist moder
cost growth
 mani competitor increas focu sanofi still conglomer
plan spin
think sanofi reach strong core portfolio commit divers strong
anim health busi pharma rejuven invest pipelin excel
 primari care divis praluent trend
sanofi still import asset primari care praluent
growth driver especi
leverag go market strategi renew focu primari care
effici sanofi take advantag
 design haemophilia go weekli extend beyond weekli
prematur disclos need fda feedback pharmacokinet offer
 oper incom growth
includ profit lose partnership net
receiv partnership profit posit base case mayb
abl get late
 china growth proport plavix avapro slow
lost tender
continu posit china growth significantli open door
innov expens price pressur establish product tender
total sale
plavix avapro sanofi estim sale two product impact
san assum gradual implement
whole countri
third
 ikaria data stack versu competit
need preserv data put present risk primari endpoint met
toler accept hope data shorter infus time far less
steroid pre-treat work new
 see solid tumour combo data pdx
data variou solid tumour type trickl cours hope
uniqu featur isatuximab could immune-suppress metabolit tumour
microenviron would synergist pdx
 level unmet need agglutinin diseas soliri good price analogu
cad seriou diseas well known physician sanofi increas
invest doc educ ahead trial readout ultra rare diseas sanofi think
pt us eu price much depend data
trial would assum price accord valu deliv
 sanofi respons propos chang us rebat medicar
sanofi fulli understand cost pressur patient frustrat lack
transpar drug price sanofi would like see save net price pass
patient sanofi believ elimin safe harbour would lead short-term
uncertainti import step toward achiev share goal reduc pocket
cost applaud administr make chang reduc patient
pocket sanofi need time understand impact
realli realli pleas initi launch curv number perspect see
use allergist encourag uptak pulmonologist especi
low prior asthma biolog use alway said scope biolog use
expans dupix well place self administrstio good efficaci co-
morbid commerci live establish criteria see great
includ bivv ablynx debt cost off-set increas valu
financi invest still encourag aim rebal debt mix toward us
 given base gm go
mix diabet price declin impact part donut hole reason
declin gm sale replac antibodi sale high
gm small molecul peak
 discontinu diabet program john reed refocu futur
develop mid-stag
remain interest next gen incretin obes particular first molecul
clinic right ratio agonist other come tri agonist
clinic later year remain much scope also test
delay releas technolog peptid drug ideal would abl bring
togeth tri agonist extend dose format
 see swing profit jv
commerci partnership becom profit
acceler strongli sg ramp flatten sale continu grow confid
strong benefit partnership beyond profit
 dupix market roll
ad adolesc potenti ad paediatr high
preval kid clear proport patient use biolog
children also clear efficaci paediatr allerg asthma clear
proport parent would consid biolog san give detail
expect get closer launch
 jak come ad think competit threat
valu oral vs inject dermatolog
sanofi access info market date san best
profil efficaci safeti derm want oral also focus
safeti eye jak safeti set san pt dupix
build safeti efficaci profil real world still earli stage
ad market new entrant like drive market penetr grow
market well posit continu growth
 think biosimilar lantu substitut
march long act insulin other regul biolog
pathway acceler approv somewhat like gener fda releas draft
guidanc base guidelin substitut grant march
deadlin would need switch studi recal us lantu much smaller
proport sanofi diabet sanofi group
 good access asthma driven discount
san believ qualiti product good experi ad excel
data asthma innov still reward certainli discount
 busi develop left bivv ablynx
time deal
spent integr ablynx bivv gone well chang potenti
diseas area interest opportunist note strengthen oncolog
immunolog look replac aubagio ms come year
saw slowdown due hemlibra earli adopt
haemophilia patient switch therapi eloct disproport
cannibalis haemophilia dynam favour patient short-act
factor prophi lot room grow
fitisuran gene therapi pipelin complet portfolio set sanofi
long run keep sanofi leader
 increas optimis
larg envelop john charg pharma budget medic
spend life-cycl plan look focus medic budget real-world evid
studi sanofi get better conduct clinic trial look synergi cost
charl martineau univers toronto save prioritis import go forward rigor look
result submiss
 eloct consensu high
sanofi expect continu grow stay competit
earli day earli access program countri feedback
good satisfact physician patient patient show
decreas number day hospit big launch us
gbu diabet cardiovascular ex em
number share outstand fd
busi ep fd
compani mention price
